Fernand Labrie
Publications
Page 6 of 8, showing 50 records out of 368 total, starting on record 251, ending on 300
| Publication | Category | Year |
|---|---|---|
| 252. Labrie, F., Dupont, A., Bélanger, A. (1986) Blocco totale degli androgeni nel trattamento del cancro della prostata. Essex Oncologia, 3-47. | Prostate Cancer | 1986 |
| 253. Labrie, F., Dupont, A., Bélanger, A. (1986) Combined therapy with an LHRH agonist and a pure antiandrogen in prostate cancer, in: Paulson, J.D., Negro-Vilar, A., Lucena, E. et Martini, L., eds: Andrology: Male Fertility and Sterility, New York, Academic Press, pp 39-55. | Prostate Cancer | 1986 |
| 254. Labrie, F., Dupont, A., Bélanger, A. (1986) LHRH analogues in prostate cancer. Lancet, Vol. I: 445-446. | Prostate Cancer | 1986 |
| 234. Labrie, F., Dupont, A., Bélanger, A. (1987) LHRH agonists and antiandrogens in prostate cancer, in: Catalona, W.J. et Ratliff, T.L., eds: Genitourinary Cancer, Boston, Martinus Nijhoff Publishing, pp 157-200. | Prostate Cancer | 1987 |
| 185. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Brochu, M., Turina, E., Pinault, S., Lacourcière, Y., Emond, J. (1989) Anti-hormone treatment in stage D2 prostate cancer patients relapsing under treatment with Flutamide and castration: addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br. J. Urol., 63: 634-638. | Prostate Cancer | 1989 |
| 235. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Giguère, M., Lacourcière, Y., Luthy, I., Bégin, D., Labrie, C., Simard, J., Monfette, G., Emond, J. (1987) Combination therapy in stage C and D prostatic cancer: rationale and 5-year clinical experience, in: Poste, G. et Fidler, I.J., eds: Cancer and Metastatic Reviews, Boston, Martinus Nijhoff Publishing, pp 615-636. | Prostate Cancer | 1987 |
| 314. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourcière, Y., Monfette, G., Laberge, J.G., Emond, J., Fazekas, A.T.A., Raynaud, J.P., Husson, J.M. (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and antiandrogen. Clin. Invest. Med., 5: 267-275. | Prostate Cancer | 1982 |
| 289. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G. (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA, 81: 3861-3863. | Prostate Cancer | 1984 |
| 236. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G., Luthy, I., Simard, J., Lachance, R. (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J. Drug Develop., 1: 34-51. | Prostate Cancer | 1987 |
| 237. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Bergeron, N., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration in prostate cancer: four years of experience, in: D'Agata, R. et Chrousos, G.P., eds: Recent Advances in Adrenal Regulation and Function, New York, Raven Press, pp 209-221. | Prostate Cancer | 1987 |
| 238. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G. (1987) Combined blockade with a pure antiandrogen (Flutamide) should be used without interruption in all patients with previously untreated or treated advanved prostate cancer, in: Beaulieu, E.E., Lacobelli, S. et McGuire, W.L., eds: Endocrinology and Malignancy - Basic and Clinical Issues. Proc. First International Congress on Cancer and Hormones, London, The Parthenon Publishing Group, pp 348-360. | Prostate Cancer | 1987 |
| 239. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy): the minimal endocrine therapy in prostate cancer, in: McCann, S.M. et Weiner, R., eds: Integrative Neuroendocrinology: Molecular Cellular and Clinical Aspects, S. Karger, A.G. Basel, pp 220-234. | Prostate Cancer | 1987 |
| 240. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides growth factors and new (anti)-steroidal agents. Monograph Series of the Europea, New York, Raven Press, pp 291-300. | Prostate Cancer | 1987 |
| 274. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem., 23: 833-841. | Prostate Cancer | 1985 |
| 306. Labrie, F., Dupont, A., Bélanger, A., Husson, J.M., Raynaud, J.P. (1983) Nouveau traitement antihormonal avec un antiandrogène et un agoniste de la LHRH dans le cancer de la prostate. Ann. Endocrinol. (Paris), 44: 343-344. | Prostate Cancer | 1983 |
| 290. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Emond, J., Monfette, G., Houle, J.G., Girard, J.G., Vallières, A., Bossé, C., Delisle, R. (1984) Dramatic response of prostate cancer to complete antihormonal treatment, in: Bracci, U. et Silverio, F.D., eds: Advances in Urological Oncology and Endocrinology, Rome, Acta Medica, Edizione E Congressi, pp 233-248. | Prostate Cancer | 1984 |
| 291. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Emond, J., Houle, J.G., Girard, J.G., Monfette, G., Paquet, J.P., Vallières, A., Bossé, C., Delisle, R. (1984) Combined antihormonal treatment in prostate cancer: a new approach using an LHRH agonist or castration and an antiandrogen, in: Bresciani, F., King, R.J.B., Lippman, M.E. et Raynaud, J.P., eds: Hormones and cancer 2: Proceedings of the Second International Congress on Hormones and Cancer, New York, Raven Press, pp 533-547. | Prostate Cancer | 1984 |
| 241. Labrie, F., Dupont, A., Bélanger, A., Lachance, R. (1987) Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. J. Urol., 138: 804-806. | Prostate Cancer | 1987 |
| 275. Labrie, F., Dupont, A., Bélanger, A., Lachance, R., Giguère, M. (1985) Long-term treatment with luteinizing hormone-releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br. Med. J. (Clin. Res. Ed.), 291: 369-370. | Prostate Cancer | 1985 |
| 292. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1984) Combined antiandrogen blockade in adenocarcinoma of the prostate: the first application of a successful new therapeutic principle in hormone-dependent cancer, in: Arvis, G., ed. Second International Forum on Andrology, Expansion Scientifique Française, Paris, pp 163-196. | Prostate Cancer | 1984 |
| 276. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G., Bergeron, V. (1985) Antiandrogènes et agonistes de la LHRH dans le traitement du cancer de la prostate. Médecine/Sciences, 1: 435-439. | Prostate Cancer | 1985 |
| 255. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Giguère, M., Emond, J., Monfette, G. (1986) Traitement antiandrogénique combiné dans l'adénocarcinome de la prostate: première application d'un nouveau principe thérapeutique dans le cancer hormono-dépendant. Ann. Urol. (Paris), 20: 98-106. | Prostate Cancer | 1986 |
| 293. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Members of LUPCP. (1984) Complete androgen blockade at start of treatment causes a dramatic improvement of survival in advanced prostate cancer, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its analogues: Basic and Clinical Aspects, Excerpta Medica, pp 368-379. | Prostate Cancer | 1984 |
| 307. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Gareau, J., Fazekas, A.T.A., Sandow, J., Monfette, G. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate, 4: 579-594. | Prostate Cancer | 1983 |
| 308. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Monfette, G., Laberge, J.G., Emond, J.P., Raynaud, J.P., Husson, J.M., Fazekas, A.T.A. (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J. Steroid Biochem., 19: 999-1007. | Prostate Cancer | 1983 |
| 309. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Raynaud, J.P., Husson, J.M., Fazekas, A.T. (1983) New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Horm. Res., 18: 18-27. | Prostate Cancer | 1983 |
| 310. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Raynaud, J.P. (1983) Nouvelle approche dans le traitement du cancer de la prostate: utilisation combinée d'un agoniste de la LHRH et d'un antiandrogène. J. Pharmacol. (Paris), 14 Suppl 3: 117-135. | Prostate Cancer | 1983 |
| 294. Labrie, F., Dupont, A., Bélanger, A., Members of LUPCP (1984) Spectacular response to combined antihormonal treatment in advanced prostate cancer, in: Labrie, F. et Proulx, L., eds: Endocrinology ICS 655, Excerpta Medica, pp 450-453. | Prostate Cancer | 1984 |
| 256. Labrie, F., Dupont, A., Bélanger, A., Poyet, P., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G., Borsanyi, J.P. (1986) Combined treatment with Flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer. Lancet, 327: 48-49. | Prostate Cancer | 1986 |
| 207. Labrie, F., Dupont, A., Bélanger, A., Simard, J., Labrie, C., Poulin, R., Luthy, I., Veilleux, R., Lacoste, D., Marchetti, B., Cusan, L., Manhès, G., Monfette, G., Emond, J. (1988) Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, in: Chretien, M. et McKerns, K.W., eds: Molecular Biology of Brain and Endocrine Peptidergic Systems, New York, Plenum Press, pp 83-101. | Prostate Cancer | 1988 |
| 257. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Combined treatment with an LHRH agonist and the antiandrogen Flutamide in prostate cancer, in: Moody, T.W., ed. Neural Endocrine Peptides and Receptors, New York, Plenum Press, pp 627-644. | Prostate Cancer | 1986 |
| 258. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Giguère, M., Lacourcière, Y., Emond, J., Monfette, G. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev., 7: 67-74. | Prostate Cancer | 1986 |
| 295. Labrie, F., Dupont, A., Bélanger, A., St-Arnaud, R., Labrie, C., Members of LUPCP (1984) Medical castration with LHRH agonists and the need for combined treatment with an antiandrogen in prostate cancer, in: McKerns, K.W., ed. Hormonal Control of the Hypothalamic-Pituitary Gonadal Axis, New York, Plenum Press, pp 531-549. | Prostate Cancer | 1984 |
| 208. Labrie, F., Dupont, A., Cusan, L., Bélanger, A., Giguère, M., Labrie, C., Lacourcière, Y., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C and D prostate cancer: Today's therapy of choice - Rationale and 5-year clinical experience. Prog. Clin. Biol. Res., 262: 11-63. | Prostate Cancer | 1988 |
| 209. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Emond, J., Monfette, G., Boucher, H., Lachance, R. (1988) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J. Steroid Biochem., 30: 107-117. | Prostate Cancer | 1988 |
| 210. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide in advanced (stages C and D) previously untreated prostate cancer, in: Motta, M. et Serio, M., eds: Hormonal therapy of prostatic diseases: basic and clinical aspects: International Symposium, Milano, Italy, April 6-8 1987: abstracts of lectures and free communications, pp 312-333. | Prostate Cancer | 1988 |
| 186. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1989) Terapia combinada con flutamida y (D-TRP6)LH-RH etilamida en el cancer de prostata en estadio D2 sin tratamiento previo, in: Pontes, J.E., Mallo, N. et Zungri, E., eds: Cancer de Prostata, ulso Ediciones, Barcelona, Actualizaciones Urologicas, pp 73-86. | Prostate Cancer | 1989 |
| 141. Labrie, F., Dupont, A., Cusan, L., Gomez, J.-L., Diamond, P. (1993) Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med., 16: 493-498. | Prostate Cancer | 1993 |
| 187. Labrie, F., Dupont, A., Cusan, L., Labrie, C., Lacoste, D., Luu-The, V., Manhès, G., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Today's endocrine therapy of prostate cancer, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 223-235. | Prostate Cancer | 1989 |
| 188. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with castration and flutamide: to-day's treatment of choice for prostate cancer. J. Steroid Biochem., 33: 817-821. | Prostate Cancer | 1989 |
| 189. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) Combination therapy with Flutamide and castration: its benefits at various stages of prostate cancer, in: Murphy, G.P. et Khoury, S., eds: Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 161-167. | Prostate Cancer | 1989 |
| 190. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Bergeron, N., Lacourcière, Y., Pinault, S., Bélanger, A., Monfette, G., Emond, J. (1989) LHRH agonists and prostate cancer: an example of rapid development of a new class of drugs, in: Chiou, S.H., Wang, K.T. et Wu, S.H., eds: International Symposium on Biologically Active Proteins and Peptides, July 13-15, 1988, Taipei, Taiwan, pp 129-136. | Prostate Cancer | 1989 |
| 161. Labrie, F., Dupont, A., Cusan, L., Manhès, G., Lacourcière, Y., Monfette, G., Emond, J. (1991) Maximal androgen blockade in prostate cancer: To-Day's Therapy of choice and 5-year clinical experience, in: Vickery, B.H. et Lunenfeld, B., eds: International Symposium on GnRH analogues in Cancer and Human Reproduction, The Netherlands, Kluwer Academic Publishers, pp 79-102. | Prostate Cancer | 1991 |
| 260. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Br. Med. J. (Clin. Res. Ed.), 293: 1171. | Prostate Cancer | 1986 |
| 259. Labrie, F., Dupont, A., Emond, J., Monfette, G. (1986) Combination therapy in prostate cancer. Lancet, 2: 1095-1096. | Prostate Cancer | 1986 |
| 261. Labrie, F., Dupont, A., Giguère, M., Borsanyi, A., Bélanger, A., Lacourcière, Y., Emond, J., Monfette, G. (1986) Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J. Steroid Biochem., 25: 877-883. | Prostate Cancer | 1986 |
| 211. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy of LHRH agonists): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Review Article. Prog. Clin. Biol. Res., 260: 41-62. | Prostate Cancer | 1988 |
| 242. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. J. Steroid Biochem., 27: 525-532. | Prostate Cancer | 1987 |
| 212. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., Bergeron, N. (1988) Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol., 61: 341-346. | Prostate Cancer | 1988 |
| 213. Labrie, F., Dupont, A., Giguère, M., Cusan, L., Bergeron, N., Emond, J., Monfette, G., Lacourcière, Y., Boucher, H., Lachance, R. (1988) Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur. J. Cancer Clin. Oncol., 24: 1869-1878. | Prostate Cancer | 1988 |